bpc-157 compounding restrictions fda advisory committee votes to add popular peptide to drug list FDA's Overreach on Compounded Peptides
FDA's Overreach on Compounded Peptides BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) Hims & Hers Stock Jumps as FDA Panel Opens the Door to a Multibillion Dollar Peptide Market PRISM MarketView Industry Update: Interim 503A and 503B Bulks Lists New Revisions The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA is reviewing seven peptides this week, BPC 157, MOTS c, and Epitalon among them. Committee meets Thursday and Friday, and the likely outcome is tighter restrictions on compounding pharmacies. Read past the headline
Pay in 4 interest-free payments of $5.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6


